Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 170

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 170
---
 1, 2020,
through March 31, 2022. Cuts of 1% were imposed from April 1 through June 30, 2022. As of July 1, 2022, cuts of two
percent were reimposed and are set to remain in effect until 2031 unless additional Congressional action is taken. To offset the temporary
suspension during the COVID-19 pandemic, in 2030, the sequestration will be 2.25% for the first half of the year, and 3% in the second
half of the year.

While DiamiR cannot predict whether third-party reimbursement to its
customers will be adequate, cost-containment measures and similar efforts by third-party payers, including government programs such as
Medicare and Medicaid, could substantially impact the sales of its products and potentially limit its net revenue and results.

If any of its product candidates are approved, DiamiR may be adversely affected by healthcare policy changes, including additional healthcare reform and changes in managed healthcare.

Healthcare reform and the growth of managed care organizations have
been considerable forces in the medical diagnostics industry and in recent political discussions. These forces have placed, and are expected
to continue to place, constraints on the levels of overall pricing for healthcare products and services as well as the coverage available
by public and private insurance and thus, could have a material adverse effect on the future profit margins of its products or the amounts
that DiamiR are able to receive from third parties for the licensing of its products. Changes in the United States healthcare market
could also force DiamiR to alter its approach to selling, marketing, distributing and servicing its products and customer base. In and
outside the United States, changes to government reimbursement policies could reduce the funding that healthcare service providers
have available for diagnostic product expenditures, which could have a material adverse impact on the use of the products DiamiR are developing
and its future sales, license and royalty fees and profit margin.

For example, the ACA requires CMS to reduce payments to hospitals reimbursed
under Medicare’s Inpatient Prospective Payment System (“IPPS”) that have higher than expected readmissions. This and
other applicable requirements set forth under the ACA and its current and future implementing regulations may significantly increase its
costs, and/or reduce its customer’s ability to obtain adequate reimbursement for tests performed with its products, which could
adversely affect its business and financial condition. In addition to direct impacts from reimbursement cuts